Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by H. Parise
Pcn84 - Total Cost of Care and Budget Impact for Patients With CLL Treated With Venetoclax
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Venetoclax: Another Oral Therapy Option for Patients With CLL
Pharmacy Today
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax Treated CLL in Routine Clinical Practice
Clinical Cancer Research
Cancer Research
Oncology
Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pmd40 - The Budget Impact and Cost-Consequence of Treating Leg Ulcers With Urgostart
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Venetoclax–Obinutuzumab Elicits High Response Rates in CLL
Cancer Discovery
Oncology
Biclonal IGHV -4-34 Variant Hairy Cell Leukemia and CLL - Successful Treatment With Ibrutinib and Venetoclax
American Journal of Hematology
Hematology
Pmd41 - The Budget Impact and Cost-Consequence of Treating Diabetic Foot Ulcers With Urgostart
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Extended Follow-Up and Impact of High-Risk Prognostic Factors From the Phase 3 RESONATE Study in Patients With Previously Treated CLL/SLL
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
